Cardiac-derived stem cell-based therapy for heart failure

Progress and clinical applications

Yao Liang Tang, Yingjie J. Wang, Lijuan J. Chen, Yaohua H. Pan, Lan Zhang, Neal Lee Weintraub

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure, a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of sources and exhibit unique characteristics that impact their potential therapeutic utility. The adult heart contains small populations of committed, multipotent cardiac stem cells (CSC), which are adapted to the cardiac microenvironment and participate in postnatal physiological and pathological cardiac renewal or repair. These cells can be isolated, expanded in culture, and administered therapeutically to improve cardiac function in the setting of heart failure. CSC can be differentiated into three distinct cardiovascular lineages and exhibit enhanced paracrine factor production and engraftment as compared with other types of mesenchymal stem cells, which in turn may translate into improved therapeutic efficacy. The cell surface marker expression and phenotype of these CSC, however, depends on the method of isolation, selection and propagation, which likely explains the variable experimental results obtained to date. Moreover, invasive procedures are required to obtain CSC from humans. Early trials using autologous CSC in patients with ischemic cardiomyopathy have demonstrated feasibility and safety, along with variable degrees of therapeutic efficacy in terms of enhancing myocardial viability and cardiac function. Further studies are needed to optimize methods of CSC isolation, manipulation and delivery. If fully realized, the potential of CSC therapy could fundamentally change the approach to the treatment of end-stage heart failure.

Original languageEnglish (US)
Pages (from-to)294-300
Number of pages7
JournalExperimental Biology and Medicine
Volume238
Issue number3
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Stem cells
Stem Cells
Heart Failure
Multipotent Stem Cells
Cell Separation
Therapeutics
Mesenchymal Stromal Cells
Cardiomyopathies
Morbidity
Phenotype
Safety
Repair
Mortality
Population

Keywords

  • Cardiac stem cells
  • Cardiosphere
  • Heart regeneration
  • Hypoxic preconditioning
  • MicroRNA

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cardiac-derived stem cell-based therapy for heart failure : Progress and clinical applications. / Tang, Yao Liang; Wang, Yingjie J.; Chen, Lijuan J.; Pan, Yaohua H.; Zhang, Lan; Weintraub, Neal Lee.

In: Experimental Biology and Medicine, Vol. 238, No. 3, 01.03.2013, p. 294-300.

Research output: Contribution to journalArticle

Tang, Yao Liang ; Wang, Yingjie J. ; Chen, Lijuan J. ; Pan, Yaohua H. ; Zhang, Lan ; Weintraub, Neal Lee. / Cardiac-derived stem cell-based therapy for heart failure : Progress and clinical applications. In: Experimental Biology and Medicine. 2013 ; Vol. 238, No. 3. pp. 294-300.
@article{14272d54b8cd4751a3c17522f945ba63,
title = "Cardiac-derived stem cell-based therapy for heart failure: Progress and clinical applications",
abstract = "Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure, a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of sources and exhibit unique characteristics that impact their potential therapeutic utility. The adult heart contains small populations of committed, multipotent cardiac stem cells (CSC), which are adapted to the cardiac microenvironment and participate in postnatal physiological and pathological cardiac renewal or repair. These cells can be isolated, expanded in culture, and administered therapeutically to improve cardiac function in the setting of heart failure. CSC can be differentiated into three distinct cardiovascular lineages and exhibit enhanced paracrine factor production and engraftment as compared with other types of mesenchymal stem cells, which in turn may translate into improved therapeutic efficacy. The cell surface marker expression and phenotype of these CSC, however, depends on the method of isolation, selection and propagation, which likely explains the variable experimental results obtained to date. Moreover, invasive procedures are required to obtain CSC from humans. Early trials using autologous CSC in patients with ischemic cardiomyopathy have demonstrated feasibility and safety, along with variable degrees of therapeutic efficacy in terms of enhancing myocardial viability and cardiac function. Further studies are needed to optimize methods of CSC isolation, manipulation and delivery. If fully realized, the potential of CSC therapy could fundamentally change the approach to the treatment of end-stage heart failure.",
keywords = "Cardiac stem cells, Cardiosphere, Heart regeneration, Hypoxic preconditioning, MicroRNA",
author = "Tang, {Yao Liang} and Wang, {Yingjie J.} and Chen, {Lijuan J.} and Pan, {Yaohua H.} and Lan Zhang and Weintraub, {Neal Lee}",
year = "2013",
month = "3",
day = "1",
doi = "10.1177/1535370213477982",
language = "English (US)",
volume = "238",
pages = "294--300",
journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",
issn = "1535-3702",
publisher = "Society for Experimental Biology and Medicine",
number = "3",

}

TY - JOUR

T1 - Cardiac-derived stem cell-based therapy for heart failure

T2 - Progress and clinical applications

AU - Tang, Yao Liang

AU - Wang, Yingjie J.

AU - Chen, Lijuan J.

AU - Pan, Yaohua H.

AU - Zhang, Lan

AU - Weintraub, Neal Lee

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure, a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of sources and exhibit unique characteristics that impact their potential therapeutic utility. The adult heart contains small populations of committed, multipotent cardiac stem cells (CSC), which are adapted to the cardiac microenvironment and participate in postnatal physiological and pathological cardiac renewal or repair. These cells can be isolated, expanded in culture, and administered therapeutically to improve cardiac function in the setting of heart failure. CSC can be differentiated into three distinct cardiovascular lineages and exhibit enhanced paracrine factor production and engraftment as compared with other types of mesenchymal stem cells, which in turn may translate into improved therapeutic efficacy. The cell surface marker expression and phenotype of these CSC, however, depends on the method of isolation, selection and propagation, which likely explains the variable experimental results obtained to date. Moreover, invasive procedures are required to obtain CSC from humans. Early trials using autologous CSC in patients with ischemic cardiomyopathy have demonstrated feasibility and safety, along with variable degrees of therapeutic efficacy in terms of enhancing myocardial viability and cardiac function. Further studies are needed to optimize methods of CSC isolation, manipulation and delivery. If fully realized, the potential of CSC therapy could fundamentally change the approach to the treatment of end-stage heart failure.

AB - Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure, a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of sources and exhibit unique characteristics that impact their potential therapeutic utility. The adult heart contains small populations of committed, multipotent cardiac stem cells (CSC), which are adapted to the cardiac microenvironment and participate in postnatal physiological and pathological cardiac renewal or repair. These cells can be isolated, expanded in culture, and administered therapeutically to improve cardiac function in the setting of heart failure. CSC can be differentiated into three distinct cardiovascular lineages and exhibit enhanced paracrine factor production and engraftment as compared with other types of mesenchymal stem cells, which in turn may translate into improved therapeutic efficacy. The cell surface marker expression and phenotype of these CSC, however, depends on the method of isolation, selection and propagation, which likely explains the variable experimental results obtained to date. Moreover, invasive procedures are required to obtain CSC from humans. Early trials using autologous CSC in patients with ischemic cardiomyopathy have demonstrated feasibility and safety, along with variable degrees of therapeutic efficacy in terms of enhancing myocardial viability and cardiac function. Further studies are needed to optimize methods of CSC isolation, manipulation and delivery. If fully realized, the potential of CSC therapy could fundamentally change the approach to the treatment of end-stage heart failure.

KW - Cardiac stem cells

KW - Cardiosphere

KW - Heart regeneration

KW - Hypoxic preconditioning

KW - MicroRNA

UR - http://www.scopus.com/inward/record.url?scp=84877642162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877642162&partnerID=8YFLogxK

U2 - 10.1177/1535370213477982

DO - 10.1177/1535370213477982

M3 - Article

VL - 238

SP - 294

EP - 300

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

SN - 1535-3702

IS - 3

ER -